ABSTRACT:
Celecoxib is a nonsteroidal anti-inflammatory drug used in the treatment of pain and inflammation, associated with rheumatoid arthritis, and several other inflammatory disorders. The objective of this study was to develop a simple high sensitive, selective, and rapid quantitative analytical and bioanalytical method for estimation of Celecoxib as API and in biological fluids. The drug shows absorption maxima at 253nm. The linear dynamic response was found to be in the concentration of 2µg-28µg/ml. The slope, intercept and correlation coefficient were found to be 0.0342, 0.0228, and 0.9995 respectively. The percentage recovery of Celecoxib was found to be 100.28%. The extraction of the Celicoxcib from rat plasma was done by Liquid-liquid extraction method. The extraction procedure described by Lee and Min was attempted with some variations. Proposed methods were found to be simple, accurate, precise and rapid and could be used for routine analysis. This method is applied for estimation of Celecoxib as API and in biological fluids. Quantitative recoveries were obtained from plasma. The newly developed methods can be used for routine analysis of Celecoxib for bioavailability of equal significance is the recognition of the immense value of bioequivalence testing as a tool for quality control.